150 related articles for article (PubMed ID: 23845438)
1. BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?
Martin LA; Dowsett M
Cancer Cell; 2013 Jul; 24(1):7-9. PubMed ID: 23845438
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.
Vaillant F; Merino D; Lee L; Breslin K; Pal B; Ritchie ME; Smyth GK; Christie M; Phillipson LJ; Burns CJ; Mann GB; Visvader JE; Lindeman GJ
Cancer Cell; 2013 Jul; 24(1):120-9. PubMed ID: 23845444
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Labi V; Grespi F; Baumgartner F; Villunger A
Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371
[TBL] [Abstract][Full Text] [Related]
5. Restoring cancer's death sentence.
Letai A
Cancer Cell; 2006 Nov; 10(5):343-5. PubMed ID: 17097553
[TBL] [Abstract][Full Text] [Related]
6. BH3 mimetics to improve cancer therapy; mechanisms and examples.
Zhang L; Ming L; Yu J
Drug Resist Updat; 2007 Dec; 10(6):207-17. PubMed ID: 17921043
[TBL] [Abstract][Full Text] [Related]
7. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
Khaw SL; Huang DC; Roberts AW
Pathology; 2011 Oct; 43(6):525-35. PubMed ID: 21881535
[TBL] [Abstract][Full Text] [Related]
8. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
9. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.
Mason KD; Vandenberg CJ; Scott CL; Wei AH; Cory S; Huang DC; Roberts AW
Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17961-6. PubMed ID: 19004807
[TBL] [Abstract][Full Text] [Related]
11. Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.
Deng J; Letai A
Breast Cancer Res; 2013; 15(5):317. PubMed ID: 24172207
[TBL] [Abstract][Full Text] [Related]
12. ABT-737, proving to be a great tool even before it is proven in the clinic.
Vaux DL
Cell Death Differ; 2008 May; 15(5):807-8. PubMed ID: 18408737
[No Abstract] [Full Text] [Related]
13. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
Lieber J; Armeanu-Ebinger S; Fuchs J
Int J Mol Sci; 2015 Feb; 16(2):4190-208. PubMed ID: 25690034
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.
Mani J; Antonietti P; Rakel S; Blaheta R; Bartsch G; Haferkamp A; Kögel D
World J Urol; 2016 Feb; 34(2):197-205. PubMed ID: 26100943
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 inhibitors reduce steroid-insensitive airway inflammation.
Tian BP; Xia LX; Bao ZQ; Zhang H; Xu ZW; Mao YY; Cao C; Che LQ; Liu JK; Li W; Chen ZH; Ying S; Shen HH
J Allergy Clin Immunol; 2017 Aug; 140(2):418-430. PubMed ID: 28043871
[TBL] [Abstract][Full Text] [Related]
17. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
18. Targeting the B-cell lymphoma/leukemia 2 family in cancer.
Davids MS; Letai A
J Clin Oncol; 2012 Sep; 30(25):3127-35. PubMed ID: 22649144
[TBL] [Abstract][Full Text] [Related]
19. [Effect and significance of BH3-only protein in targeted therapy of
non-small cell lung cancer].
Gao W; Huang W; Liu K
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):819-23. PubMed ID: 25404273
[TBL] [Abstract][Full Text] [Related]
20. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
Yalniz FF; Wierda WG
Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
